Sickle cell disease (SCD) is a monogenetic disorder due to a single base-pair point mutation
in the β-globin gene resulting in the substitution of the amino acid valine for glutamic acid in …

Sickle cell disease (SCD) is a group of inherited disorders affecting red blood cells, which is
caused by a single mutation that results in substitution of the amino acid valine for glutamic …

Background Hydroxyurea (HU) is an evidence-based therapy that is currently the most
effective drug for sickle cell disease (SCD). HU is widely used in high-income countries with …

Background: Hydroxyurea is underutilized by sickle cell health-care providers in Nigeria
despite available evidence of its effectiveness in reducing the manifestations and …

Background: Hydroxyurea (HU) is a disease‐modifying therapy with significant clinical and
laboratory efficacy among individuals living with sickle cell anaemia (SCA). This is evident …

People living with sickle cell anaemia (SCA) tend to experience multiple sources of therapy
complemented by self-care practices. In Nigeria, over 100,000 babies are born yearly with …

Background: Sickle cell anemia (SCA) is an autosomal recessive disorder associated with
high morbidity and mortality in children. Hydroxyurea (HU) has shown to decrease the …

Background: Although hydroxycarbamide (hydroxyurea [HU]) has been in use for decades
in both adults and child populations with sickle cell disease (SCD), its reported use has …

Sickle cell anaemia is an autosomal recessive blood disorder that has over the years been a
big burden on healthcare in Kenya and Africa as a whole. The disease tends to be caused …